PharmaCyte Biotech (PMCB) Long-Term Investments (2013 - 2026)

PharmaCyte Biotech (PMCB) has reported Long-Term Investments for 14 consecutive years, with $22.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments rose 20.62% year-over-year to $22.5 million; the TTM figure through Jan 2026 stood at $22.5 million (up 20.62% YoY), while the FY2025 annual figure was $22.5 million, changed N/A from the prior year.
• Long-Term Investments improved to $22.5 million in Q1 2026 per PMCB's latest filing, from $20.7 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $29.1 million in Q3 2024 and bottomed at $1.6 million in Q1 2022.
• Historically, Long-Term Investments has averaged $10.8 million across 5 years, with a median of $1.6 million in 2022.
• Annual changes were most pronounced in 2024 — Long-Term Investments soared 1752.19% — and 2025, when it sank 32.57%.
• PharmaCyte Biotech's Long-Term Investments stood at $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then surged by 1480.91% to $24.9 million in 2024, then dropped by 16.53% to $20.7 million in 2025, then grew by 8.31% to $22.5 million in 2026.
• Business Quant data shows PMCB's Long-Term Investments at $22.5 million in Q1 2026, $20.7 million in Q4 2025, and $19.6 million in Q3 2025.